Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX3009 phase Ib/II trial in rare EGFR-mutant advanced NSCLC
ChiCTR2500102784Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMX3009 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Phase Ib recommended phase II dose, Phase Ib adverse events and serious adverse events and 1 more. Started May 2025; status: recruiting.
02
Drugs
AMX3009
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102784.